Compare GHC & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GHC | INDV |
|---|---|---|
| Founded | 1877 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.2B |
| IPO Year | 1994 | 2014 |
| Metric | GHC | INDV |
|---|---|---|
| Price | $1,194.73 | $33.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $49.00 |
| AVG Volume (30 Days) | 25.6K | ★ 1.7M |
| Earning Date | 10-28-2026 | 10-29-2026 |
| Dividend Yield | ★ 0.63% | N/A |
| EPS Growth | N/A | ★ 8100.00 |
| EPS | ★ 71.04 | 1.67 |
| Revenue | ★ $2,932,099,000.00 | $1,239,000,000.00 |
| Revenue This Year | $5.98 | $7.50 |
| Revenue Next Year | $4.03 | $5.07 |
| P/E Ratio | ★ $16.86 | $20.12 |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $974.00 | $23.72 |
| 52 Week High | $1,262.35 | $42.81 |
| Indicator | GHC | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 67.83 | 33.24 |
| Support Level | $1,104.70 | $32.06 |
| Resistance Level | $1,221.02 | $35.70 |
| Average True Range (ATR) | 24.79 | 1.03 |
| MACD | 6.04 | -0.23 |
| Stochastic Oscillator | 90.66 | 0.27 |
Graham Holdings Company is a diversified holding company with operations spanning educational services, television broadcasting, healthcare, manufacturing, automotive dealerships, and other businesses. The Company's education activities are conducted through Kaplan, whose services include academic preparation programs for international students, English-language programs, exam preparation, and career and academic advisement. These services are provided to students, schools, and colleges, both domestically and outside the United States. It operates through seven reportable segments: Kaplan International, Kaplan Higher Education, Kaplan Supplemental Education, Television Broadcasting, CSI, Manufacturing and Automotive, with key revenue coming from the Education and Automotive segments.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).